Look into the Safety Data

This image is for illustrative purposes only.

The safety profile of Lumirix® is established in Phase 3 studies with up to 104 weeks of exposure.10,16,17

At 52 weeks of treatment​

At 52 weeks, Lumirix® was generally well-tolerated. The majority of application‑site reactions were mild and
transient. Serious treatment‑related adverse events were infrequent.​

Ruxolitinib cream was well-tolerated​​

No clinically significant application site reactions or serious treatment-related AEs.2​​

*Occurring in ≥4% of patients in any treatment group. †No serious TEAEs were considered rested to trestment.

Click to read study design

At 104 weeks of treatment​​​

Ruxolitinib cream 104-week safety profile was consistent with TRuE-V1/V2 (52 weeks) and no new safety
signals were reported.16,17​​​​

Ruxolitinib cream from day 1 and vehicle to ruxolitinib cream at week 24 indicate the treatment arms of the TRuE-V LTE study.
a Treatment-related TEAEs in patients applying ruxolitinib cream 1.5% bid were application-site dermatitis (n=1), application-site rash (n=1), and hyperlipidemia (n=1) in cohort A and application-site pruritus (n=4; 1.2%) in cohort B.2

Reference

  1. Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. New England Journal of Medicine. 2022 Oct 20;387(16):1445-55. Supplementary material.
  1. Harris JE, et al. Presented at American Academy of Dermatology Annual Meeting; March 17–21, 2023; New Orleans, LA, USA; late-breaker presentation.
  2. Rosmarin D, et al. Presented at American Academy of Dermatology Annual Meeting; March 17–21, 2023; New Orleans, LA, USA; late-breaker presentation.